Discovery of (2R)-N-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor

被引：43

作者：

Su, Qibin ^{[1
]}

Banks, Erica ^{[1
]}

Bebernitz, Geraldine ^{[1
]}

Bell, Kirsten ^{[1
]}

Borenstein, Cassandra F. ^{[1
]}

Chen, Huawei ^{[1
]}

Chuaqui, Claudio E. ^{[1
]}

Deng, Nanhua ^{[1
]}

Ferguson, Andrew D. ^{[2
,3
]}

Kawatkar, Sameer ^{[1
]}

Grimster, Neil P. ^{[1
]}

Ruston, Linette ^{[1
]}

Lyne, Paul D. ^{[1
]}

Read, Jon A. ^{[3
]}

Peng, Xianyou ^{[4
]}

Pei, Xiaohui ^{[4
]}

Fawell, Stephen ^{[1
]}

Tang, Zhanlei ^{[4
]}

Throner, Scott ^{[1
]}

Vasbinder, Melissa M. ^{[1
]}

Wang, Haoyu ^{[4
]}

Winter-Holt, Jon ^{[5
]}

Woessner, Richard ^{[1
]}

Wu, Allan ^{[2
]}

Yang, Wenzhan ^{[6
]}

Zinda, Michael ^{[1
]}

Kettle, Jason G. ^{[5
]}

机构：

[1] AstraZeneca R&D, Oncol R&D, Waltham, MA 02451 USA

[2] AstraZeneca R&D, R&D, Discovery Sci, Waltham, MA 02451 USA

[3] AstraZeneca R&D, R&D, Discovery Sci, Cambridge CB4 0WG, England

[4] Pharmaron Beijing Co Ltd, Beijing 100176, Peoples R China

[5] AstraZeneca R&D, Oncol R&D, Cambridge CB4 0WG, England

[6] R&D, Pharmaceut Sci, Early Product Dev, Boston, MA 02451 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2020年 / 63卷 / 09期

关键词：

PATENT LITERATURE 2013-2015; JAK-FAMILY KINASES; RHEUMATOID-ARTHRITIS; INADEQUATE RESPONSE; STAT3; ACTIVATION; PATHWAY; CANCER; IDENTIFICATION; PROLIFERATION; PEFICITINIB;

D O I：

10.1021/acs.jmedchem.9b01392

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

JAK1, JAK2, JAK3, and TYK2 belong to the JAK (Janus kinase) family. They play critical roles in cytokine signaling. Constitutive activation of JAK/STAT pathways is associated with a wide variety of diseases. Particularly, pSTAT3 is observed in response to the treatment with inhibitors of oncogenic signaling pathways such as EGFR, MAPK, and AKT and is associated with resistance or poorer response to agents targeting these pathways. Among the JAK family kinases, JAK1 has been shown to be the primary driver of STAT3 phosphorylation and signaling; therefore, selective JAK1 inhibition can be a viable means to overcome such treatment resistances. Herein, an account of the medicinal chemistry optimization from the promiscuous kinase screening hit 3 to the candidate drug 21 (AZD4205), a highly selective JAK1 kinase inhibitor, is reported. Compound 21 has good preclinical pharmacokinetics. Compound 21 displayed an enhanced antitumor activity in combination with an approved EGFR inhibitor, osimertinib, in a preclinical non-small-cell lung cancer (NSCLC) xenograft NCI-H1975 model.

引用

页码：4517 / 4527

页数：11

共 50 条

[41] Discovery of 2-((1H-benzo[d]imidazol-1-yl) methyl)-4H-pyrido [1,2-a]pyrimidin-4-ones as novel PKM2 activators [J].

Guo, Chuangxing ;

Linton, Angelica ;

Jalaie, Mehran ;

Kephart, Susan ;

Ornelas, Martha ;

Pairish, Mason ;

Greasley, Samantha ;

Richardson, Paul ;

Maegley, Karen ;

Hickey, Michael ;

Li, John ;

Wu, Xin ;

Ji, Xiaodong ;

Xie, Zhi .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (11) :3358-3363

[42] Discovery of a potent tyrosine kinase AXL inhibitor bearing the 3-((2,3,4,5-tetrahydro-1H-benzo [d] azepin-7-yl)amino)pyrazine core [J].

Wang, Yueliang ;

Xing, Li ;

Ji, Yinchun ;

Ye, Jiqing ;

Dai, Yang ;

Gu, Wangting ;

Ai, Jing ;

Song, Zilan .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2019, 29 (06) :836-838

[43] Discovery of 4-Amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides As Selective, Orally Active Inhibitors of Protein Kinase B (Akt) [J].

McHardy, Tatiana ;

Caldwell, John J. ;

Cheung, Kwai-Ming ;

Hunter, Lisa J. ;

Taylor, Kevin ;

Rowlands, Martin ;

Ruddle, Ruth ;

Henley, Alan ;

Brandon, Alexis de Haven ;

Valenti, Melanie ;

Davies, Thomas G. ;

Fazal, Lynsey ;

Seavers, Lisa ;

Raynaud, Florence I. ;

Eccles, Suzanne A. ;

Aherne, G. Wynne ;

Garrett, Michelle D. ;

Collins, Ian .

JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (05) :2239-2249

[44] 3-(1,2,3-Triazol-4-yl)-β-Carbolines and 3-(1H-Tetrazol-5-yl)-β-Carbolines: Synthesis and Evaluation as Anticancer Agents [J].

Ribeiro, Joao L. P. ;

Loureiro, Joana B. ;

Lopes, Susana M. M. ;

Saraiva, Lucilia ;

Pinho e Melo, Teresa M. V. D. .

PHARMACEUTICALS, 2022, 15 (12)

[45] Design and synthesis of novel 3-(benzo[d]oxazol-2-yl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine derivatives as selective G-protein-coupled receptor kinase-2 and -5 inhibitors [J].

Cho, Sung Yun ;

Lee, Byung Ho ;

Jung, Heejung ;

Yun, Chang Soo ;

Du Ha, Jae ;

Kim, Hyoung Rae ;

Chae, Chong Hak ;

Lee, Jeong Hyun ;

Seo, Ho Won ;

Oh, Kwang-Seok .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (24) :6711-6716

[46] Utility of MetaSite in Improving Metabolic Stability of the Neutral Indomethacin Amide Derivative and Selective Cyclooxygenase-2 Inhibitor 2-(1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)-N-phenethyl-acetamide [J].

Boyer, David ;

Bauman, Jonathan N. ;

Walker, Daniel P. ;

Kapinos, Brendon ;

Karki, Kapil ;

Kalgutkar, Amit S. .

DRUG METABOLISM AND DISPOSITION, 2009, 37 (05) :999-1008

[47] Design, synthesis and anticancer activity of N-(1-(4-(dibenzo[bf][1,4] thiazepin-11-yl)piperazin-1-yl)-1-oxo-3-phenylpropan-2-yl derivatives [J].

Gudisela, Mura Reddy ;

Srinivasu, N. ;

Mulakayala, Chaitanya ;

Bommu, Praveen ;

Rao, M. V. Basaveswara ;

Mulakayala, Naveen .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (17) :4140-4145

[48] Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl) pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl) piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of cancers [J].

Barlaam, Bernard ;

Cosulich, Sabina ;

Delouvrie, Bebedicte ;

Ellston, Rebecca ;

Fitzek, Martina ;

Germain, Herve ;

Green, Stephen ;

Hancox, Urs ;

Harris, Craig S. ;

Hudson, Kevin ;

Lambert-van der Brempt, Christine ;

Lebraud, Honorine ;

Magnien, Franoise ;

Lamorlette, Maryannick ;

Le Griffon, Antoine ;

Morgentin, Remy ;

Ouvry, Gilles ;

Page, Ken ;

Pasquet, Georges ;

Polanska, Urszula ;

Ruston, Linette ;

Saleh, Twana ;

Vautier, Michel ;

Ward, Lara .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (22) :5155-5162

[49] Discovery of (R)-6-Cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a Potent and Orally Available Hepatitis C Virus Polymerase Inhibitor [J].

Li, Hui ;

Tatlock, John ;

Linton, Angelica ;

Gonzalez, Javier ;

Jewell, Tanya ;

Patel, Leena ;

Ludlum, Sarah ;

Drowns, Matthew ;

Rahavendran, Sadayappan V. ;

Skor, Heather ;

Hunter, Robert ;

Shi, Stephanie T. ;

Herlihy, Koleen J. ;

Parge, Hans ;

Hickey, Michael ;

Yu, Xiu ;

Chau, Fannie ;

Nonomiya, Jim ;

Lewis, Cristina .

JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (05) :1255-1258

[50] Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity [J].

Boezio, Alessandro A. ;

Copeland, Katrina W. ;

Rex, Karen ;

Albrecht, Brian K. ;

Bauer, David ;

Bellon, Steven F. ;

Boezio, Christiane ;

Broome, Martin A. ;

Choquette, Deborah ;

Coxon, Angela ;

Dussault, Isabelle ;

Hirai, Satoko ;

Lewis, Richard ;

Lin, Min-Hwa Jasmine ;

Lohman, Julia ;

Liu, Jingzhou ;

Peterson, Emily A. ;

Potashman, Michele ;

Shimanovich, Roman ;

Teffera, Yohannes ;

Whittington, Douglas A. ;

Vaida, Karma ;

Harmange, Jean-Christophe .

JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (06) :2328-2342

← 1 2 3 4 5 →